Literature DB >> 27131769

Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction.

Abiodun Adefurin1, Leon Darghosian1, Chimalum Okafor1, Vivian Kawai1, Chun Li2, Anushi Shah3, Wei-Qi Wei3, Daniel Kurnik4, C Michael Stein1.   

Abstract

BACKGROUND: Acute myocardial infarction (AMI) is frequently associated with transient hyperglycemia even in patients without pre-existing diabetes. Acute stress can lead to increased blood glucose through the effect of catecholamines on alpha2A-adrenergic receptors (α2A-ARs) present in pancreatic islet β-cells. Variation in the gene (ADRA2A) that encodes the α2A-AR affects insulin release and glucose control and may play a particularly important role during times of stress.
METHODS: We performed a retrospective cohort study using de-identified electronic medical records linked to a DNA repository in 521 Caucasians and 55 African-American non-diabetic patients with AMI. We examined the association between admission blood glucose concentrations and ten selected ADRA2A SNPs in Caucasians.
RESULTS: Three ADRA2A SNPS were associated with stress-induced hyperglycemia in Caucasians. Individuals homozygous for the rs10885122 variant (n=9) had a 23% lower admission glucose (geometric mean [95% CI], 99 [83-118]mg/dl) compared with non-carriers (121 [118-125] mg/dl; n=401; P=0.001). Admission glucose was 14% higher in rs1800544 variant homozygotes (134 [119-150]mg/dl; n=36) compared to non-carriers (118 [115-121]mg/dl; n=290, P=0.046). Furthermore, homozygotes of the rs553668 variant (n=13) had a 13% higher glucose (133 [110-160]mg/dl) compared to non-carriers (118 [115-122]mg/dl; n=366; P=0.056). Haplotypes including these ADRA2A SNPs were associated with higher admission glucose levels.
CONCLUSIONS: Three ADRA2A genetic variants are associated with blood glucose and stress-induced hyperglycemia after AMI in Caucasians.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alpha adrenergic receptors; Glucose; Stress

Mesh:

Substances:

Year:  2016        PMID: 27131769      PMCID: PMC4879094          DOI: 10.1016/j.ijcard.2016.04.079

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  37 in total

Review 1.  Glucose-lowering targets for patients with cardiovascular disease: focus on inpatient management of patients with acute coronary syndromes.

Authors:  Mikhail Kosiborod; Darren K McGuire
Journal:  Circulation       Date:  2010-12-21       Impact factor: 29.690

Review 2.  Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction.

Authors:  Stuart W Zarich; Richard W Nesto
Journal:  Circulation       Date:  2007-05-08       Impact factor: 29.690

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White
Journal:  Glob Heart       Date:  2012-09-26

4.  Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.

Authors:  Siti Norsyuhada Roffeei; Gavin P Reynolds; Nor Zuraida Zainal; Mas Ayu Said; Ahmad Hatim; Syarinaz Ahmad Aida; Zahurin Mohamed
Journal:  Hum Psychopharmacol       Date:  2013-11-25       Impact factor: 1.672

5.  Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain.

Authors:  Y-C Wang; Y-M Bai; J-Y Chen; C-C Lin; I-C Lai; Y-J Liou
Journal:  J Neural Transm (Vienna)       Date:  2005-03-30       Impact factor: 3.575

6.  Impact of stress hyperglycemia on in-hospital stent thrombosis and prognosis in nondiabetic patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.

Authors:  Jian-Wei Zhang; Yu-Jie Zhou; Shu-Jun Cao; Qing Yang; Shi-Wei Yang; Bin Nie
Journal:  Coron Artery Dis       Date:  2013-08       Impact factor: 1.439

7.  Glucose normalization and outcomes in patients with acute myocardial infarction.

Authors:  Mikhail Kosiborod; Silvio E Inzucchi; Harlan M Krumholz; Frederick A Masoudi; Abhinav Goyal; Lan Xiao; Philip G Jones; Suzanne Fiske; John A Spertus
Journal:  Arch Intern Med       Date:  2009-03-09

8.  Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma.

Authors:  Jeffrey D Kerby; Russell L Griffin; Paul MacLennan; Loring W Rue
Journal:  Ann Surg       Date:  2012-09       Impact factor: 12.969

9.  The alpha 2-adrenergic receptor gene and body fat content and distribution: the HERITAGE Family Study.

Authors:  Christophe Garenc; Louis Pérusse; Yvon C Chagnon; Tuomo Rankinen; Jacques Gagnon; Ingrid B Borecki; Arthur S Leon; James S Skinner; Jack H Wilmore; D C Rao; Claude Bouchard
Journal:  Mol Med       Date:  2002-02       Impact factor: 6.354

10.  Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans.

Authors:  M R Goldberg; A S Hollister; D Robertson
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

View more
  5 in total

1.  Variation in the α2A-adrenergic receptor gene and risk of gestational diabetes.

Authors:  Vivian K Kawai; Rebecca T Levinson; Abiodun Adefurin; Daniel Kurnik; Sarah P Collier; Douglas Conway; Charles Michael Stein
Journal:  Pharmacogenomics       Date:  2017-10-04       Impact factor: 2.533

Review 2.  Role of adrenergic receptor signalling in neuroimmune communication.

Authors:  Sushanta Chhatar; Girdhari Lal
Journal:  Curr Res Immunol       Date:  2021-11-25

3.  Pharmacodynamic Gene Testing in Prader-Willi Syndrome.

Authors:  Janice Forster; Jessica Duis; Merlin G Butler
Journal:  Front Genet       Date:  2020-11-20       Impact factor: 4.599

4.  Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients.

Authors:  Annika M A Berends; Mathieu S Bolhuis; Ilja M Nolte; Edward Buitenwerf; Thera P Links; Henri J L M Timmers; Richard A Feelders; Elisabeth M W Eekhoff; Eleonora P M Corssmit; Peter H Bisschop; Harm R Haak; Ron H N van Schaik; Samira El Bouazzaoui; Bob Wilffert; Michiel N Kerstens
Journal:  Biomedicines       Date:  2022-04-13

5.  Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist.

Authors:  Magdalena Kotańska; Katarzyna Kulig; Monika Marcinkowska; Marek Bednarski; Katarzyna Malawska; Paula Zaręba
Journal:  J Endocrinol Invest       Date:  2017-11-07       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.